363 related articles for article (PubMed ID: 20576610)
21. Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.
Gunther EC; Strittmatter SM
J Mol Med (Berl); 2010 Apr; 88(4):331-8. PubMed ID: 19960174
[TBL] [Abstract][Full Text] [Related]
22. Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.
Aimi T; Suzuki K; Hoshino T; Mizushima T
J Neurochem; 2015 Aug; 134(4):611-7. PubMed ID: 25963375
[TBL] [Abstract][Full Text] [Related]
23. Development of Alkaline Phosphatase-Fused Mouse Prion Protein and Its Application in Toxic Aβ Oligomer Detection.
Tsukakoshi K; Kubo R; Ikebukuro K
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498917
[TBL] [Abstract][Full Text] [Related]
24. Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death.
Kudo W; Lee HP; Zou WQ; Wang X; Perry G; Zhu X; Smith MA; Petersen RB; Lee HG
Hum Mol Genet; 2012 Mar; 21(5):1138-44. PubMed ID: 22100763
[TBL] [Abstract][Full Text] [Related]
25. Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1.
Rushworth JV; Griffiths HH; Watt NT; Hooper NM
J Biol Chem; 2013 Mar; 288(13):8935-51. PubMed ID: 23386614
[TBL] [Abstract][Full Text] [Related]
26. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance.
Smith LM; Kostylev MA; Lee S; Strittmatter SM
J Biol Chem; 2019 Apr; 294(15):6042-6053. PubMed ID: 30787106
[TBL] [Abstract][Full Text] [Related]
27. The pathogenesis of soluble PrP fragments containing Aβ binding sites.
Li B
Virus Res; 2016 Jan; 211():194-8. PubMed ID: 26528810
[TBL] [Abstract][Full Text] [Related]
28. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
29. Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.
Chen RJ; Chang WW; Lin YC; Cheng PL; Chen YR
ACS Chem Neurosci; 2013 Sep; 4(9):1287-96. PubMed ID: 23805846
[TBL] [Abstract][Full Text] [Related]
30. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
[TBL] [Abstract][Full Text] [Related]
31. PrP N-terminal domain triggers PrP(Sc)-like aggregation of Dpl.
Erlich P; Cesbron JY; Lemaire-Vieille C; Curt A; Andrieu JP; Schoehn G; Jamin M; Gagnon J
Biochem Biophys Res Commun; 2008 Jan; 365(3):478-83. PubMed ID: 17997980
[TBL] [Abstract][Full Text] [Related]
32. Identification of a Compound That Disrupts Binding of Amyloid-β to the Prion Protein Using a Novel Fluorescence-based Assay.
Risse E; Nicoll AJ; Taylor WA; Wright D; Badoni M; Yang X; Farrow MA; Collinge J
J Biol Chem; 2015 Jul; 290(27):17020-8. PubMed ID: 25995455
[TBL] [Abstract][Full Text] [Related]
33. Interaction between prion protein and Aβ amyloid fibrils revisited.
Nieznanski K; Surewicz K; Chen S; Nieznanska H; Surewicz WK
ACS Chem Neurosci; 2014 May; 5(5):340-5. PubMed ID: 24669873
[TBL] [Abstract][Full Text] [Related]
34. Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity.
Nieznanski K; Choi JK; Chen S; Surewicz K; Surewicz WK
J Biol Chem; 2012 Sep; 287(40):33104-8. PubMed ID: 22915585
[TBL] [Abstract][Full Text] [Related]
35. Unaltered prion protein expression in Alzheimer disease patients.
Saijo E; Scheff SW; Telling GC
Prion; 2011; 5(2):109-16. PubMed ID: 21654203
[TBL] [Abstract][Full Text] [Related]
36. Prion protein and Alzheimer disease.
Kellett KA; Hooper NM
Prion; 2009; 3(4):190-4. PubMed ID: 19887909
[TBL] [Abstract][Full Text] [Related]
37. Residue-specific mobility changes in soluble oligomers of the prion protein define regions involved in aggregation.
Glaves JP; Ladner-Keay CL; Bjorndahl TC; Wishart DS; Sykes BD
Biochim Biophys Acta Proteins Proteom; 2018 Sep; 1866(9):982-988. PubMed ID: 29935976
[TBL] [Abstract][Full Text] [Related]
38. Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy.
König AS; Rösener NS; Gremer L; Tusche M; Flender D; Reinartz E; Hoyer W; Neudecker P; Willbold D; Heise H
J Biol Chem; 2021; 296():100499. PubMed ID: 33667547
[TBL] [Abstract][Full Text] [Related]
39. The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid β.
Iida M; Mashima T; Yamaoki Y; So M; Nagata T; Katahira M
FEBS J; 2019 Jun; 286(12):2355-2365. PubMed ID: 30916478
[TBL] [Abstract][Full Text] [Related]
40. Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease.
Salazar SV; Strittmatter SM
Biochem Biophys Res Commun; 2017 Feb; 483(4):1143-1147. PubMed ID: 27639648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
